Please login to the form below

Fycompa

This page shows the latest Fycompa news and features for those working in and with pharma, biotech and healthcare.

Eisai did likewise for its epilepsy treatment Fycompa (perampanel).

Eisai establishes neuroscience unit in Belgium and Luxembourg

The new unit will market the company's epilepsy drug Fycompa (perampanel), which it has been giving a rolling launch across the region. ... Fycompa indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised
Eisai opens first office in Australia

New Melbourne base to support marketing of Halaven and Fycompa. Japan-based pharma firm Eisai has extended its global expansion with a new office in Melbourne, Australia. ... Fycompa is the first in a new class of treatment for partial onset seizures,
Eisai "speechless" as G-BA denies price premium for Fycompa

But company has better news on cancer drug Halaven. . Eisai's efforts to secure favourable pricing for its epilepsy drug Fycompa in Germany have hit the buffers once again. ... The German Federal Joint Committee (G-BA) has concluded once again that
Eisai backs competition to find star of epilepsy comic book

Epilepsy is a relative new area of focus for Eisai, whose treatment options include Fycompa (perampanel), which was launched in Europe in 2012.
Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug

Eisai has issued a damning statement criticising Germany's healthcare watchdog IQWIG for not backing epilepsy drug Fycompa. ... IQWIG's recommendation will now be considered by the G-BA, which is expected to published a decision on Fycompa's use in

More from news
Approximately 10 fully matching, plus 9 partially matching documents found.

Eisai: Bucking the trend with R&D growth

by adding a new solid dose global manufacturing line for its anti-epileptic medicine Fycompa. ... Fycompa was the first Eisai-developed epilepsy drug and it's “a drug we can really differentiate”, says Hendler.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

EU Head of Business Development and Client Service: Exceptional packge and bonus

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Home based, Senior Medical Writer, Medical Communications: Excellent package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Add my company

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....